Home » Authors » Kim Coghill

Articles by Kim Coghill

Santarus Gets FDA Approval For Rapinex Powder Version

June 17, 2004

Axonyx Begins Second Pivotal Phenserine Trial In Alzheimer's

June 17, 2004

InterMune Begins Phase III Trial Of Once-Daily Infergen

June 16, 2004

InterMune Inc. started a Phase III trial to evaluate the once-daily use of Infergen in combination with ribavirin for patients chronically infected with hepatitis C virus who have failed to respond to a previous course of therapy with pegylated interferon alfa-2 plus ribavirin. (BioWorld Today)

InterMune Begins Phase III Trial Of Once-Daily Infergen

June 16, 2004

InterMune Inc. started a Phase III trial to evaluate the once-daily use of Infergen in combination with ribavirin for patients chronically infected with hepatitis C virus who have failed to respond to a previous course of therapy with pegylated interferon alfa-2 plus ribavirin. (BioWorld Today)

Alexion, P&G Get FDA Clearance On Pexelizumab Phase III Design

June 15, 2004

OSI Reports Anticipated Negative Results In Aptosyn Phase III Trial

June 15, 2004

OSI Reports Anticipated Negative Results In Aptosyn Phase III Trial

June 15, 2004

Alexion, P&G Get FDA Clearance On Pexelizumab Phase III Design

June 15, 2004

Momentum Growing For Effort To Legalize Drug Importation

June 14, 2004

NCI, CMS Begin Initiative To Improve Information On Cancer

June 14, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...